Cargando…
Topical Application of Hyaluronic Acid-RGD Peptide-Coated Gelatin/Epigallocatechin-3 Gallate (EGCG) Nanoparticles Inhibits Corneal Neovascularization via Inhibition of VEGF Production
Neovascularization (NV) of the cornea disrupts vision which leads to blindness. Investigation of antiangiogenic, slow-release and biocompatible approaches for treating corneal NV is of great importance. We designed an eye drop formulation containing gelatin/epigallocatechin-3-gallate (EGCG) nanopart...
Autores principales: | Miyagawa, Takuya, Chen, Zhi-Yu, Chang, Che-Yi, Chen, Ko-Hua, Wang, Yang-Kao, Liu, Guei-Sheung, Tseng, Ching-Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284559/ https://www.ncbi.nlm.nih.gov/pubmed/32354067 http://dx.doi.org/10.3390/pharmaceutics12050404 |
Ejemplares similares
-
Epigallocatechin-3-gallate (EGCG) inhibits the migratory behavior of tumor bronchial epithelial cells
por: Hazgui, Salma, et al.
Publicado: (2008) -
Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG)
por: Singh, Neha Atulkumar, et al.
Publicado: (2016) -
Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization
por: Chang, Che-Yi, et al.
Publicado: (2016) -
Enoxacin and Epigallocatechin Gallate (EGCG) Act Synergistically to Inhibit the Growth of Cervical Cancer Cells in Culture
por: McDonnell, Anna Margaret, et al.
Publicado: (2019) -
Antioxidant and antiviral activities of lipophilic epigallocatechin gallate (EGCG) derivatives
por: Zhong, Ying, et al.
Publicado: (2012)